280 related articles for article (PubMed ID: 11280722)
1. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.
Haubner R; Wester HJ; Weber WA; Mang C; Ziegler SI; Goodman SL; Senekowitsch-Schmidtke R; Kessler H; Schwaiger M
Cancer Res; 2001 Mar; 61(5):1781-5. PubMed ID: 11280722
[TBL] [Abstract][Full Text] [Related]
2. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner R; Wester HJ; Reuning U; Senekowitsch-Schmidtke R; Diefenbach B; Kessler H; Stöcklin G; Schwaiger M
J Nucl Med; 1999 Jun; 40(6):1061-71. PubMed ID: 10452325
[TBL] [Abstract][Full Text] [Related]
4. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.
Haubner R; Kuhnast B; Mang C; Weber WA; Kessler H; Wester HJ; Schwaiger M
Bioconjug Chem; 2004; 15(1):61-9. PubMed ID: 14733584
[TBL] [Abstract][Full Text] [Related]
5. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.
Beer AJ; Haubner R; Sarbia M; Goebel M; Luderschmidt S; Grosu AL; Schnell O; Niemeyer M; Kessler H; Wester HJ; Weber WA; Schwaiger M
Clin Cancer Res; 2006 Jul; 12(13):3942-9. PubMed ID: 16818691
[TBL] [Abstract][Full Text] [Related]
7. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
8. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
[TBL] [Abstract][Full Text] [Related]
9. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
10. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
Chen X; Park R; Tohme M; Shahinian AH; Bading JR; Conti PS
Bioconjug Chem; 2004; 15(1):41-9. PubMed ID: 14733582
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging.
Su ZF; Liu G; Gupta S; Zhu Z; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2002; 13(3):561-70. PubMed ID: 12009947
[TBL] [Abstract][Full Text] [Related]
12. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
15. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging.
Ogawa M; Hatano K; Oishi S; Kawasumi Y; Fujii N; Kawaguchi M; Doi R; Imamura M; Yamamoto M; Ajito K; Mukai T; Saji H; Ito K
Nucl Med Biol; 2003 Jan; 30(1):1-9. PubMed ID: 12493537
[TBL] [Abstract][Full Text] [Related]
16. Radiosynthesis and biodistribution of a prosthetic group (¹⁸F-FENMA) conjugated to cyclic RGD peptides.
Olberg DE; Cuthbertson A; Solbakken M; Arukwe JM; Qu H; Kristian A; Bruheim S; Hjelstuen OK
Bioconjug Chem; 2010 Dec; 21(12):2297-304. PubMed ID: 21070000
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.
Liu S; Hsieh WY; Jiang Y; Kim YS; Sreerama SG; Chen X; Jia B; Wang F
Bioconjug Chem; 2007; 18(2):438-46. PubMed ID: 17341108
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.
Beer AJ; Haubner R; Goebel M; Luderschmidt S; Spilker ME; Wester HJ; Weber WA; Schwaiger M
J Nucl Med; 2005 Aug; 46(8):1333-41. PubMed ID: 16085591
[TBL] [Abstract][Full Text] [Related]
19. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
20. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
